Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eclipse Surgical

This article was originally published in The Gray Sheet

Executive Summary

Brightened image through name change to CardioGenesis is foreseen by the transmyocardial revascularization system developer. Announced June 18, the change reflects plans to offer a broader range of products for cardiovascular disease, possibly including delivery systems for growth factor compounds. The new appellation is taken from a March 1999 acquisition by the same name. The firm's stock symbol also changes June 21 to "CGCP." The Sunnyvale, California company simultaneously announces plans to move its headquarters from Silicone Valley to Foothill Ranch, California by August to cut expenses. A PMA supplement for the firm's percutaneous myocardial revascularization system is scheduled for FDA panel review July 9...

You may also be interested in...

COVID-19 Vaccine 'Brexit Bonus' A Myth

The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.

Warning Letter Close-Outs – November 2020

The US Food and Drug Administration posted two device-related closeout letters in November.

Jazz And PharmaMar’s Zepzelca Hits Buffers In ATLANTIS Study

Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts